Results 41 to 50 of about 75,992 (272)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies

CPT: Pharmacometrics & Systems Pharmacology, 2019
Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal ...
Jason Zhang, Kinjal Sanghavi, Jun Shen, Xiaochen Zhao, Yan Feng, Paul Statkevich, Jennifer Sheng, Amit Roy, Li Zhu   +8 more
doaj   +1 more source

Nivolumab Efficacy and Safety in Cancer Patients with Renal Dysfunction [PDF]

Aim: Immune checkpoint inhibitors have transformed cancer treatment; however, clinical trials often exclude patients with renal dysfunction. This study aimed to evaluate the efficacy and safety of nivolumab in this population, addressing the limited ...
Gulcin Sahingoz Erdal, Caner Kapar, Mesut Yilmaz, Ezgi Degerli, Ayse Gul Satman Durmaz, Esra Turan Canbaz, Rumeysa Colak, Deniz Tural   +7 more
core   +1 more source

Nivolumab-induced lichen planus

, 2020
Introduction:Renal cell carcinomas account for 90% of all malignant neoplasms of the kidney. The most common types of renal cancer in adults are clear cell and papillary renal cell carcinoma; sporadic cases of renal carcinomas containing chromosomal ...
Çelik, Uğur, Güven Meşe, Şermin, Yılmaz, Mesut   +2 more
core   +1 more source

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Frontiers in Pharmacology, 2022
Objective: Nivolumab improves overall survival (OS) and is associated with fewer adverse events than sorafenib for the treatment of advanced hepatocellular carcinoma (aHCC).
Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, Xiaoyu Chen   +5 more
doaj   +1 more source

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma:a randomised, open-label, phase 2 trial

, 2022
Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies.
Xu, Li, Yao, James C, Qayyum, Aliya, Jindal, Sonali, Mohamed, Yehia I., Allison, James Patrick, Vauthey, Jean-Nicolas, Yao, James C., Beretta, Laura, Kaseb, Ahmed Omar, Xiao, Lianchun, Chun, Yun Shin, Lee, Sunyoung S., Lee, Sunyoung S, Carter, Kristen, Yavuz, Betul Gok, Sun, Jing Jing, Basu, Sreyashi, Cristini, Vittorio, Duan, Fei, Yadav, Shalini S, Sakamuri, Divya, Sharma, Padmanee, Nicholas, Courtney, Wolff, Robert A, Vauthey, Jean Nicolas, Singh Raghav, Kanwal Pratap, Wolff, Robert A., Cao, Hop Sanderson Tran, Yadav, Shalini S., Tzeng, Ching Wei David, Sun, Ryan, Hasanov, Elshad, Rashid, Asif, Tzeng, Ching-Wei David, Mohamed, Yehia I   +35 more
core   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

World Journal of Surgical Oncology, 2020
Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer ...
Jingjie Chen, Shengnan Li, Qigu Yao, Nannan Du, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang   +10 more
doaj   +1 more source

Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune‐related adverse events and favorable outcome

Cancer Medicine, 2023
Introduction Immune‐related adverse events (irAEs) are prognostic factors for patients on nivolumab. However, predictors of irAEs have not yet been identified.
Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Arata Horii   +7 more
doaj   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome

Arthritis Care &Research, EarlyView.
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino, Grant W. Cannon, Brian C. Sauer, Jorge Rojas, Gregory J. Stoddard, Gary A. Kunkel, Jessica A. Walsh, Bryant R. England, Joshua F. Baker, Tawnie J. Braaten   +9 more
wiley   +1 more source